Efficacy and Safety of Filgotinib in Rheumatoid Arthritis Patients Aged over and under 65 Years (ENANTIA-65).
Maurizio BenucciMarco BardelliMassimiliano CazzatoFrancesca BartoliArianna DamianiFrancesca Li GobbiFrancesca BandinelliAnna PanaccioneLuca Di CatoLaura NiccoliBruno FredianiMarta MoscaSerena GuiducciFabrizio CantiniPublished in: Journal of personalized medicine (2024)
After six months of treatment with FIL, the older population group showed a higher level of LDL and a lower level of HDL compared to younger patients. The atherogenic index and coronary risk index are higher in patients aged ≥ 65 years, but interestingly, there were no differences when comparing the 6-month data to baseline values. This condition highlights the impact of typical risk factors that act independently of treatment with Filgotinib.
Keyphrases
- end stage renal disease
- risk factors
- ejection fraction
- newly diagnosed
- rheumatoid arthritis patients
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- coronary artery disease
- heart failure
- physical activity
- rheumatoid arthritis
- systemic lupus erythematosus
- disease activity
- machine learning
- electronic health record
- replacement therapy